JAMA Netw Open:美国60年随访研究首次发现,儿童期接种卡介苗还能预防肺癌

2019-09-26 朱柳媛 中国循环杂志

我们都知道,卡介苗是预防肺结核而接种的一种疫苗,目前我国新生儿免费接种。

我们都知道,卡介苗是预防肺结核而接种的一种疫苗,目前我国新生儿免费接种。
 
9月25日发表在JAMA网络开放子刊上的一项随访60年的美国回顾性研究表明,儿童期接种卡介苗还有预防肺癌的作用。
 
研究者发现,60年随访期间,校正性别、地区、过度饮酒、吸烟、肺结核等因素后,接种卡介苗的人群中肺癌发生风险比未接种卡介苗者降低了62%。
 
不过,接种卡介苗的人群中癌症总发生率并没有下降(HR=0.82, 95% CI:0.66-1.02)。
 
研究者指出,该研究是首个发现接种卡介苗有肺癌预防作用的研究。接种卡介苗可产生持久的肺结核预防作用,该研究接种卡介苗的人群中肺癌风险的降低与既往结核病史无关。
 
卡介苗的这种保护作用的具体机制目前未知,可能与免疫系统被训练(trained immunity)有关。
 
该研究一共纳入2963名既往无结核病史的20岁以下学生,其中1540人幼年时接种卡介苗,其余1423人未接受卡介苗。这些接种卡介苗的人是在8岁左右时接种的。随访期间两组中各有7%的人失访。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1734173, encodeId=32201e3417315, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Nov 05 18:23:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716546, encodeId=6d6f1e165468a, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Fri Feb 14 16:23:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728150, encodeId=24981e2815034, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jul 19 16:23:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373329, encodeId=3cce3e3329d6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 29 05:56:57 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2019-11-05 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1734173, encodeId=32201e3417315, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Nov 05 18:23:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716546, encodeId=6d6f1e165468a, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Fri Feb 14 16:23:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728150, encodeId=24981e2815034, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jul 19 16:23:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373329, encodeId=3cce3e3329d6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 29 05:56:57 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2020-02-14 habb
  3. [GetPortalCommentsPageByObjectIdResponse(id=1734173, encodeId=32201e3417315, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Nov 05 18:23:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716546, encodeId=6d6f1e165468a, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Fri Feb 14 16:23:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728150, encodeId=24981e2815034, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jul 19 16:23:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373329, encodeId=3cce3e3329d6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 29 05:56:57 CST 2019, time=2019-09-29, status=1, ipAttribution=)]
    2020-07-19 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1734173, encodeId=32201e3417315, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Nov 05 18:23:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1716546, encodeId=6d6f1e165468a, content=<a href='/topic/show?id=afa5984e47a' target=_blank style='color:#2F92EE;'>#随访研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98474, encryptionId=afa5984e47a, topicName=随访研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9c1232248438, createdName=habb, createdTime=Fri Feb 14 16:23:00 CST 2020, time=2020-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728150, encodeId=24981e2815034, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sun Jul 19 16:23:00 CST 2020, time=2020-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373329, encodeId=3cce3e3329d6, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d551998554, createdName=1e1c07bdm01(暂无匿称), createdTime=Sun Sep 29 05:56:57 CST 2019, time=2019-09-29, status=1, ipAttribution=)]

相关资讯

盘点:欧洲泌尿外科学《European Urology》期刊十月文章一览。

对于在前期使用ADT+多西他赛针对mCNPC治疗,之后进展至mCRPC的患者,疾病发生进展之后再使用多西紫杉醇时,其疗效仅在有限的患者中观察到。针对此项研究中设置的患者,阿比特龙和恩杂鲁胺保持了其疗效。

Aeras全新数据:结核疫苗可以预防高危青少年患者的持续感染

Aeras是一家在美国马里兰州和南非开普顿均设有办事处的非赢利性生物技术机构,其使命是推进全世界结核病疫苗的发展。近日,Aeras宣布了一项创新性临床试验结果,结果表明结核疫苗可以预防高危青少年患者的持续感染。

盘点目前一些常见的免疫疗法

说起癌症,我们想到的多是化疗、放疗、手术等借助外部力量的治疗。但近几年,一种革命性的抗癌疗法正在兴起,并渐渐改变癌症治疗的格局,它就是免疫疗法。这是一种利用人体自身免疫系统对抗癌症的治疗。

2018 WHO意见书:卡介苗

2018年2月,世界卫生组织(WHO)发布了关于卡介苗的意见书,文章针对卡介苗的存储,运输以及疫苗接种等提供更新信息。

卡介苗可长期改善1型糖尿病患者的血糖

近一个世纪来,为防止结核病的发生,卡介苗已有30多年的应用历史,其目的是促进细胞因子--肿瘤坏死因子(TNF)的产生,TNF可帮助消除攻击个体胰岛beta细胞的的自身反应性T细胞

2018 ESMO:KEYNOTE-057研究:卡介苗治疗无效的高风险非肌层浸润性膀胱癌,帕博利珠单抗显疗效

2018 年欧洲肿瘤内科学会(ESMO)年会在德国慕尼黑举行,ESMO年会是欧洲最负盛名和最有影响力的肿瘤学会议,在世界上享有盛誉。本届ESMO年会的主题是“Securing access to optimal cancer care”。当地时间2018年10月20日的下午的Proffered paper session-非前列腺的泌尿生殖系肿瘤专场上,来自荷兰鹿特丹Erasmus MC 癌症研究